Cfra set a €70.00 ($86.42) target price on Stada Arzneimittel (ETR:SAZ) in a research report sent to investors on Monday, March 12th. The brokerage currently has a sell rating on the stock.
SAZ has been the topic of several other research reports. Nord/LB set a €74.40 ($91.85) price objective on Stada Arzneimittel and gave the stock a sell rating in a research note on Wednesday, November 29th. Commerzbank set a €66.25 ($81.79) price objective on Stada Arzneimittel and gave the stock a sell rating in a research note on Tuesday, December 26th. Warburg Research set a €74.40 ($91.85) price objective on Stada Arzneimittel and gave the stock a sell rating in a research note on Wednesday, December 20th. Finally, Independent Research set a €89.00 ($109.88) price objective on Stada Arzneimittel and gave the stock a neutral rating in a research note on Wednesday, December 20th. Five analysts have rated the stock with a sell rating and two have assigned a hold rating to the stock. The company has a consensus rating of Sell and an average price target of €73.49 ($90.73).
SAZ stock opened at €84.24 ($104.00) on Monday. Stada Arzneimittel has a 52 week low of €53.41 ($65.94) and a 52 week high of €90.24 ($111.41). The company has a market capitalization of $5,270.00 and a P/E ratio of 61.49.
COPYRIGHT VIOLATION WARNING: “Stada Arzneimittel (ETR:SAZ) Given a €70.00 Price Target by Cfra Analysts” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/03/21/stada-arzneimittel-saz-pt-set-at-70-00-by-cfra.html.
Stada Arzneimittel Company Profile
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux.
Receive News & Ratings for Stada Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stada Arzneimittel and related companies with MarketBeat.com's FREE daily email newsletter.